Gibson Dunn has advised HealthCare Royalty and Blue Owl Capital, and Latham & Watkins has advised BridgeBio Pharma. HealthCare Royalty and Blue Owl Capital have acquired...
HealthCare Royalty and Blue Owl Capital Acquire BridgeBio Pharma’s BEYONTTRA Royalty Interest for $300 Million
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
Bora Pharmaceuticals’ $210 Million Acquisition of Upsher-Smith Laboratories
Gibson, Dunn & Crutcher LLP is representing Bora Pharmaceuticals in its acquisition of Upsher-Smith Laboratories. Bora Pharmaceuticals Co., Ltd. announced the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer...



























